Donald Trump’s phony war on high prescription drug prices, explained
From the article:
Pfizer ended up agreeing to postpone its price hikes for now. The president was happy to take credit for that news, even if all he had really won was a temporary delay. Certainly not a “massive” cut.
“It’s not much of a policy win,” Rachel Sachs, a Washington University in St. Louis law professor who follows the drug prices policy debate, told me by email. “A temporary rollback in price increases by one company is far from the ‘voluntary, massive’ drops in drug prices he predicted would come several weeks ago.”
Read more here!fda health care finance health law policy pharmaceuticals rachel sachs regulation